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Introduction
 Pakistan is a large South Asian country with 
a population of over 180 million. The Section of 
Histopathology at the Aga Khan University Hospital 
in Karachi (Pakistan’s largest city) is the biggest and 
premier center for Histopathology in Pakistan. We receive 
specimens from the entire country through our collection 
points located throughout Pakistan. We annually report 
over 50,000 cases of surgical pathology.
 We commonly see cases of benign prostatic hyperplasia 
(BPH) and prostatic adenocarcinoma in our practice, and 
our studies have shown that prostatic carcinoma is among 
the commonest malignancies in older males (Zubair et 
al., 2007a; 2007b). In the West, owing to the availability 
of other treatment options e.g. pharmacologic for BPH, 
the frequency of transurethral resection (TUR) or open 
transvesical prostatectomy (enucleation) specimens has 
greatly reduced (Epstein and Netto, 2010). However, 
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this is not the case in Pakistan where the treatment of 
BPH remains overwhelmingly surgical. In fact, TUR and 
enucleation are performed for diagnostic and therapeutic 
purposes even in those cases where there is clinical 
suspicion of carcinoma. These cases include nonpalpable 
tumors with raised serum prostate specific antigen (PSA) 
levels (clinical stage T1c), and palpable tumors (clinical 
stage T2 or T3). Serum PSA testing is becoming more 
common in Pakistan, and the number of prostatic needle 
biopsies (and T1c cancers detected on these) is also 
increasing albeit gradually. However, the majority of 
prostatic adenocarcinomas in Pakistan are still diagnosed 
on TUR or open transvesical prostatectomy specimens.
 We had earlier published two studies on radical 
prostatectomy specimens and needle biopsies (Memon 
et al., 2009; Ahmad et al., 2012) The aim of the current 
study is to present the overall clinical and histological 
perspective of benign and malignant prostatic disease as 
seen in our practice.
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Materials and Methods
 All consecutive prostatic specimens (TUR, 
enucleation and needle biopsies) received in the Section 
of Histopathology, Department of Pathology and 
Microbiology, Aga Khan University Hospital, Karachi 
over a six month period (July 1 to December 31, 2012) 
were included in the study. Cases of both BPH and 
adenocarcinoma were included. All specimens were 
processed and reported according to standard protocols. 
All relevant data was recorded and analyzed using 
commercially available SPSS 19.0 software package. 
Fisher exact and chi square tests were used to calculate 
p-values for different variables. P-value equal to or less 
than 0.05 was considered significant.
Results 
 A total of 785 prostate specimens were received 
during the study period. These included 621 (79.1%) 
TUR specimens, 80 (10.2%) enucleation specimens, 
and 84 (10.7%) needle biopsies. Out of 785 cases, 595 
(75.8%) were benign, while 190 (24.2%) were malignant 
(carcinoma). The breakup of all 785 cases is shown in 
Table 1. BPH was most commonly seen in the seventh 
decade. The decade wise breakup of BPH is shown in 
Table 2. Age range of BPH was 41 to 92 years. The weight 
of BPH specimens treated by TUR ranged from 2 to 72 
grams with mean weight of 19 grams. On the other hand, 
the weight of BPH specimens treated by enucleation 
ranged from 6 to 150 grams with mean weight of 43 grams.
 Out of the 574 cases of BPH detected on TUR or 
enucleation specimens (Table 1), 28 (4.9%) had serum 
PSA in the borderline range (4-10) and a suspicion of 
malignancy was raised by the clinician. The average 
number of sections submitted in both benign (BPH) and 
malignant TUR and enucleation specimens was 3 to 4. 
However, in cases with borderline serum PSA or clinical 
suspicion of malignancy, the specimens were submitted 
entirely. Similarly, the 21 cases which turned out to be 
benign on needle biopsy (Table 1) had serum PSA in the 
borderline range. 
 Carcinoma was most commonly seen in the seventh 
decade. The decade wise breakup of cases of carcinoma 
is shown in Table 3. Age range for adenocarcinoma was 
45 to 86 years. Mean and median age was 56 and 59 years 
respectively. Overall 130 out of 190 patients (68.4%) 
were 65 years in age or older. As seen in table 1, 127 
(66.8%) out of total 190 cases of adenocarcinoma were 
detected on TUR and enucleation specimens, 53 (41.7%) 
were clinically benign (clinical stage T1a or T1b), while 
74 (58.3%) were clinically malignant. The breakup is 
shown in Table 4. Out of 53 cases which were clinically 
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Table 1. Breakup of Prostate Specimens According to 
Type of Specimen (n=785)
Type of Specimen Total No. BPH Carcinoma
1 TUR 621 527 (84.9%) 94 (15.1%)
2 Enucleation 80 47 (58.8%) 33 (41.2%)
3 Needle Biopsy 84 21 (25%) 63 (75%)
Table 2. Decade Wise Breakup of Cases of BPH (n=595)
Age (years) Number of cases Percentage (%)
1 41-50 31 5.20%
2 51-60 140 23.50%
3 61-70 239 40.20%
4 71-80 145 24.40%
5 >80 40 6.70%
Table 3. Decade Wise Breakup of Cases of Carcinoma 
(n=190)
Age (years) Number of cases Percentage (%)
1 41-50 7 3.70%
2 51-60 38 20.00%
3 61-70 74 38.90%
4 71-80 50 26.30%
5 >80 21 11.10%
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Table 6. Breakup of Gleason Score in Carcinoma 
Detected on TUR and Enucleation Specimens (n=127)
Gleason score Clinically Benign Clinically Malignant Overall
 4 --- --- --
 5 --- 2   (2.7%) 2   (1.6%)
 6 11 (20.7%) 4   (5.4%) 15 (11.8%)
 7 19 (35.8%) 23 (31.1%) 42 (33.1%)
 8 10 (18.9%) 16 (21.6%) 26 (20.5%)
 9 12 (22.7%) 29 (39.2%) 41 (32.2%)
 10 1   (1.9%) --- 1   (0.8%)
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Table 4. Breakup of Carcinomas Detected on TUR 
and Enucleation Specimens According to Clinical 
Impression (n=127)
Type of Specimen Total No. Clinically Benign Clinically Malignant
1 TUR 94 31 (33%) 63 (67%)
2 Enucleation 33 22 (66.7%) 11 (33.3%)
Table 7. Breakup of Gleason Score in Patients 65 Years 
and Older (n=130)
Gleason Score Number of cases Percentage (%)
 6 20 15.40%
 7 49 37.70%
 8 22 16.90%
 9 38 29.20%
 10 1 0.80%
Table 8. Breakup of Gleason Score 7 (n=74)
Types of specimens 3+4 4+3 Total %
Needle Biopsy 21 11 32 43.20%
Clinically benign TUR/enucleation 12 7 19 25.70%
Clinically malignant TUR/enucleation 9 14 23 31.10%
Table 5. Breakup of Gleason Score in Our Cases 
(n=190)
Gleason score Number of cases Percentage (%)
 4 --- ---
 5 2 1.00%
 6 29 15.30%
 7 74 38.90%
 8 37 19.50%
 9 47 24.70%
 10 1 0.50%
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benign, 2 (3.8%) were clinical stage T1a, while 51 (96.2%) 
were clinical stage T1b. Out of the 74 cases which were 
clinically malignant, 10 (13.5%) were T1c, while 64 
(86.5%) were T2 or T3.
 The average volume of carcinoma in clinically 
benign TUR/enucleation specimens was 60%, while 
average volume of carcinoma in clinically malignant 
TUR/enucleation specimens was 65%. Of the 63 needle 
biopsies with carcinoma, 53 (84.1%) were sextant and 10 
(15.9%) were octant. The average volume of carcinoma 
in needle biopsies was 60% and the average number of 
cores involved was 5.
 The breakup of Gleason score in all 190 cases is shown 
in Table 5. The breakup of Gleason score in clinically 
benign and clinically malignant TUR/ enucleation 
specimens is given in Table 6. As shown in Table 6, 
Gleason score was 8 or above in 43% of clinically 
benign and 61% of clinically malignant TUR/enucleation 
specimens. The p-value was significant (0.013). In needle 
biopsies, Gleason score was 6 in 14 cases (22.2%), 7 in 
32 cases (50.8%), 8 in 11 cases (17.5%) and 9 in 6 cases 
(9.5%). Out of the 63 needle biopsies with carcinomas, 
radical prostatectomy was performed in 16 cases (25.4%).
 As mentioned above, 130 (68.4%) of patients with 
carcinoma were 65 years or older. The average volume 
of carcinoma in specimens from these patients was 63%. 
The breakup of Gleason score in these 130 patients is 
shown in Table 7. Out of 190 patients, 60 (31.6%) were 
under 65 years of age. The average volume of carcinoma 
in these patients was 57%. In these 60 patients, Gleason 
score was 6 in 7 cases (11.7%), 7 in 20 cases (33.3%), 
8 in 13 cases (21.7%), 9 in 18 cases (30%) and 10 in 2 
cases (3.3%). So Gleason score was 7 and above in almost 
85% patients who were 65 years or older and in over 88% 
patients under 65 years of age. The difference was not 
statistically significant (p-value 0.578).
 A total of 74 cases of carcinoma out of 190 had Gleason 
score 7. Of these, 42 had Gleason grade 3+4=7, and 32 
had Gleason grade 4+3=7. The breakup is shown in Table 
8. So, Gleason score 7 was overall the commonest score 
in our series followed by Gleason score 9.
 As shown in Table 6 and in our results above, almost 
86% of all TUR/enucleation specimens showed a Gleason 
score 7 or above, while almost 73% of needle biopsies had 
a Gleason score 6 or 7. The difference was statistically 
significant (p-value: 0.000).
Discussion
Benign prostatic hyperplasia is extremely common 
and constitutes the bulk of prostatic specimens. As seen 
in our results, most cases of BPH are treated by TUR 
rather than suprapubic prostatectomy, although studies 
have shown that chances of a patient undergoing another 
surgery for BPH is much higher after TUR than suprapubic 
prostatectomy (Roos et al., 1989). The mean weight of 
BPH specimens in our series was 19 grams for TUR 
and 43 grams for enucleation specimens. According to 
literature, the average weight of BPH specimens obtained 
by TUR and enucleation is around 33 (±16) and 100 grams 
respectively (Rosai, 2011).
Clinical staging of prostatic adenocarcinoma is based 
on the TNM system (Epstein et al., 2007).
Clinical stage T1a and T1b carcinomas are tumors 
that are not suspected clinically and are discovered in 
TUR or enucleation specimens removed for BPH. T1a is 
carcinoma involving less than 5% of the specimen, while 
T1b is carcinoma involving more than 5% of the specimen 
(Epstein and Netto, 2010). Clinical stage T1a carcinomas 
may only be monitored with serum PSA levels, however 
sometimes radical prostatectomy is performed (Larsen et 
al., 1991). T1b carcinomas are usually treated by radical 
prostatectomy or radiotherapy (Christensen et al., 1990). 
Clinical stage T1c carcinomas are non-palpable tumors 
which are diagnosed by needle biopsy in patients with 
raised serum PSA levels. T1c carcinomas are usually 
treated by radical prostatectomy. Clinical stage T2 
carcinomas are palpable tumors which are still confined 
to the prostate. T2 carcinomas are also usually treated by 
radical prostatectomy. Clinical stage T3 carcinomas are 
tumors which have extended beyond the prostate and are 
usually treated by radiotherapy (Epstein and Netto, 2010).
The majority of prostatic carcinomas in our practice are 
still diagnosed on TUR or enucleation specimens. Owing 
to the availability of non-surgical treatment options, the 
number of TUR and enucleation specimens has declined 
in the west (Epstin and Netto, 2010). However, this is 
not the case in our country, and TUR and enucleation 
specimens remain the most common prostatic specimens 
received in the surgical pathology laboratory. As shown 
in the results, the overwhelming majority of clinically 
unsuspected carcinomas which were discovered in TUR 
or enucleation specimens performed for BPH (i.e. clinical 
stage T1a or T1b) were T1b (more than 5% of the specimen 
involved by the tumor). The presence of carcinoma in 
a TUR specimen may signify extensive spread from 
the periphery of the gland. The probability of detecting 
carcinoma in TUR specimens is directly related to the 
amount of sampling (Newman et al., 1982). If five to eight 
blocks are submitted, all clinical stage T1b carcinomas are 
detected, and if eight to ten blocks are submitted, more 
than 90% stage T1a carcinomas are detected (Murphy 
et al., 1986; Vollmer 1986; Eble and Epstein, 1990). 
Remaining tissue should be submitted if cancer is stage 
T1a, but not if cancer is stage T1b (McDowell et al., 
1994). The average volume of carcinoma in our clinical 
stage T1 cases was 60%. The fact that an average of three 
to four blocks was originally submitted in these cases 
indicates the presence of extensive and widespread cancer. 
One plausible reason why we see so much carcinoma in 
ostensibly benign cases is that no investigations e.g. serum 
PSA, transrectal ultrasound (TRUS) were carried out in 
many of these cases. It must be noted that carcinoma can 
diffusely infiltrate the gland without causing a palpable 
nodule. At other times, the carcinoma may be well defined 
and peripherally located but may remain unpalpable for 
reasons that are still not clear (Epstein and Netto, 2010). 
However, the main reason in our scenario probably is 
the failure to carry out any investigations due to lack of 
availability of these tests, patient non-affordability etc.
Our results show that the majority (58.3%) of 
carcinomas detected on TUR or enucleation specimens 
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were clinically malignant (clinical stage T2 or T3). 
However, even in such cases, TUR or enucleation rather 
than radical prostatectomy was performed, simply because 
the latter option is not available anywhere in Pakistan 
except at our center in Karachi. This is the situation in 
a country with a population of 180 million people. As 
shown in table 4, as many as 67% of carcinomas detected 
on TUR and over 33% detected on enucleation specimens 
were clinically malignant. Following TUR or enucleation, 
these patients then underwent radiotherapy. As shown in 
the results, TUR or enucleation was also performed in 10 
cases which were stage T1c.
The average volume of carcinoma in clinically 
malignant TUR or enucleation specimens was 65% which 
was not significantly higher than the average volume of 
60% seen in clinically benign T1 specimens. Only 33% of 
carcinomas in our series were detected on needle biopsies. 
Our practice does not demonstrate the trend of most cases 
being diagnosed on needle biopsies which is evident even 
in some Asian countries (Kuo et al., 2012). The average 
overall volume in our needle biopsies was 60%. It may be 
mentioned here that those TUR and enucleation specimens 
which were clinically suspicious for carcinoma but in 
which no carcinoma or only limited carcinoma (involving 
less than 5% of the submitted tissue) was found, were then 
submitted entirely. The algothims for additional sampling 
of TUR specimens were followed (McDowell et al., 1994). 
Studies have shown that patients in whom carcinoma is 
discovered in clinically benign TUR specimens have 
higher rates of tumor dissemination than those diagnosed 
by needle biopsy because tumors diagnosed incidentally 
in TUR specimens are usually more advanced (Forman 
et al., 1986).
The average volume of carcinoma in patients 65 years 
or older was 63%, while in those under 65 years of age, 
it was 57%.
It is important to note at this point that tumor volume 
whether on needle biopsies or TUR is an important 
prognostic marker that correlates well with Gleason score, 
extraprostatic tumor extension, seminal vesicle invasion, 
positive surgical margins and lymph node metastases on 
radical prostatectomy specimens (Schmid and McNeal, 
1992). In fact, one study has shown that a simple visual 
estimate (eyeballing) of tumor volume is more closely 
associated with survival than serum PSA level and 
microscopic Gleason score (Vollmer, 2009). A recent study 
which looked at the current trends in visually estimated 
tumor volume found a rising incidence of very low volume 
(0-1%) tumors in radical prostatectomy specimens (Green 
et al., 2012). In needle biopsies, the number of positive 
cores and percentage of tumor in each core are very 
strong predictors of adverse prognostic features in radical 
prostatectomy specimens (Sebo et al., 2000; Freedland et 
al., 2002; 2003).
The Gleason microscopic grade of carcinoma is 
an important prognostic marker (Zincke et al., 1994). 
There is convincing evidence that microscopic Gleason 
score is superior to other variables as an independent 
prognostic marker (Lilleby et al., 2001). Various studies 
have shown good correlation between Gleason score and 
various important pathological features seen in radical 
prostatectomy specimens, and with outcome following 
radical prostatectomy and radiotherapy (Epstein et al., 
1996; Green et al., 1998; Rubin et al., 2004; Kryvenko 
et al., 2012). The International Society of Urological 
Pathology Consensus Conference modified the Gleason 
grading in 2005 (Shah et al., 2009) according to which 
Gleason grades were updated according to new criteria. 
Several studies have validated the prognostic value of 
these modifications (Billis et al., 2008; Dong et al., 2012). 
As shown in Table (5), Gleason score 7 was the commonest 
score in our series, followed by Gleason score 9. As shown 
in Table 6, higher Gleason scores (8 or 9) were more 
frequent in clinically malignant than in clinically benign 
carcinomas detected on TUR or enucleation specimens. 
On the other hand, Gleason score 6 was much more 
common in carcinomas which were clinically benign. As 
shown in table 6, about 43% of clinically benign cases 
and over 61% of clinically malignant cases had Gleason 
score 8 and above. The p-value was significant (0.013). 
Overall, in carcinomas detected on TUR or enucleation 
specimens, majority of patients had Gleason scores 7, 8 
or 9, and Gleason score 9 was, in fact, the most common 
score. On needle biopsies (see results), Gleason score 
7 was the most common (50.8%), followed by scores 6 
(22.2%) and 8 (17.5%). In needle biopsies with different 
cores showing different grades, we report the grades 
of each core separately as per recommendations. The 
highest tumor grade is selected as the grade of the entire 
case to determine treatment, regardless of the percent 
involvement (Epstein et al., 2010). As shown in table 6, 
about 86% patients with carcinoma detected on TUR or 
enucleation specimens had Gleason score 7, 8, 9 or 10, 
while 73% patients with carcinoma detected on needle 
biopsies had Gleason score 6 or 7 (see results). The p-value 
was significant (0.000). As shown in table 7, over 84% 
patients with carcinoma who were 65 years or older had 
Gleason score 7 to 10. Similarly, as shown in results, over 
88% patients who were under 65 years of age had Gleason 
scores 7 to 10. The p-value was not significant (0.578%). 
In our study, therefore, there was no significant correlation 
of age with adverse prognosis. However, a recent study 
from China (Wang et al., 2012) reported that prostatic 
cancer patients under 59 years of age had more aggressive 
disease. However, another recent study did not find any 
statistically correlation between Gleason score and age of 
the patients (Sapira and Obiorah, 2012).
Although clinical stage T1c carcinomas are usually 
treated by radical prostatectomy (Epstein et al., 2010), 
this is not the case in our country due to reasons already 
discussed above. Radical prostatectomy was performed 
in only 16 out of 63 cases (25.4%). This is only slightly 
better than what we found in an earlier study (Memon et 
al., 2009). The number of radical prostatectomies over the 
years has increased but very slowly. Currently, the total 
number performed per year is around thirty.
However, our findings on radical prostatectomy 
specimens in the present study as well as previous studies 
(Memon et al., 2009; Ahmad and Arshad, 2012) mostly 
show advanced pathologic stage with majority of cases 
showing extraprostatic extension, seminal vesicle invasion 
and positive surgical margins. Because so few radical 
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prostatectomies are performed, pathologic staging of 
prostatic carcinoma in our setting is only possible in a 
very limited number of cases. 
Recently, studies have shown the effectiveness and 
safety of brachytherapy and combined vascular endothelial 
growth factor receptor/platelet derived growth factor 
receptor (VEGFR/PDGFR) inhibitor. Therapy in the 
treatment of localized but high risk prostate cancer (Corn 
et al., 2013).
The diagnosis  and t reatment  of  prosta t ic 
adenocarcinoma is in the majority of cases suboptimal at 
best. Most patients are managed with some form of surgery 
(TUR or suprapubic prostatectomy) plus radiotherapy 
and/or antiandrogen therapy. As prostatic carcinoma in 
general is fortunately a relatively less aggressive type 
of cancer, many patients respond to some extent to the 
above mentioned forms of treatment and since the disease 
affects mainly the elderly, may infact ultimately die from 
some other cause. 
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